Drugs / MSCs-derived exosomes
MSCs-derived exosomes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04276987 | Feb → May 2020 | COVID-19 | Ruijin Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSCs-derived exosomes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04276987 ↗ |
| Known as | haMSC-Exos | “the exosomes derived from human adipose-derived MSCs (haMSC-Exos)” PMID 35619189 ↗ May 2022 |
| Known as | MSCs-Exo | “exosomes derived from allogenic adipose mesenchymal stem cells (MSCs-Exo)” NCT04276987 ↗ |
| Route | Inhaled | “aerosol inhalation of MSCs-derived exosomes” NCT04276987 ↗ |